Clinical Trial Update: Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial assessed cyclosporine ophthalmic emulsion 0.05% delivered with a PROSE device for ocular surface disease; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Surface Disease

Drugs mentioned

• Cyclosporine ophthalmic emulsion 0.05% (PROSE device delivery) (cyclosporine ophthalmic emulsion 0.05%)

Snippet

Sponsor: Boston Sight | Conditions: Ocular Surface Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-01-13